Lipids and atherosclerosis in COVID era

Webinar from September 14, 2020

Since the emergence of the pandemic due to COVID-19, we have come to learn that it is not a simple viral pneumonia. The virus also binds to endothelial cells, myocardial cells, renal tubular cells among others and triggers a multisystem inflammation, cytokine storm and thromboembolism. This can lead to cardiovascular complications such as acute coronary syndromes, myocarditis and arrythmia and multiorgan failure. The medications we use to treat the disease have drug interactions and cardiovascular consequences. With increased risk of inflammation and thrombosis, patients with atherosclerotic vascular disease and hyperlipidemia are a vulnerable group requiring frequent and continued medical attention. The COVID-19 pandemic has significantly affected the heart healthy lifestyle and access to healthcare of our patients.

In this webinar, we will discuss the consequences of COVID-19 infection for atherosclerotic vascular disease, lipids and lipid lowering medications.

Giuseppina Caligiuri

Professor MD, PhD, Research Director, Inserm, Paris, France

Alberto Corsini

Professor, PharmD, PhD, Professor of Pharmacology, University of Milan, Italy

Handrean Soran

Dr, MBChB, MSc, MD, FRCP, CCST in Endocrinology and Diabetes

Lale Tokgözoğlu

MD, FACC, FESC , Professor of Cardiology, Hacettepe University, Ankara, Turkey.